PALI (Palisade Bio) EBITDA Margin %: 0.00% (As of Mar. 2026)


PALI Palisade Bio Inc PALI
35 GF Score
Price $1.90
! 2 Warning Signs
View Full Analysis

What is Palisade Bio EBITDA Margin %?

Palisade Bio PALI +5.59% 35 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates PALI with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Palisade Bio ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Palisade Bio's EBITDA for the three months ended in Mar. 2026 was $-9.60 Mil. Palisade Bio's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Palisade Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Palisade Bio  (NAS:PALI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Palisade Bio EBITDA Margin % Related Terms

Palisade Bio EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Palisade Bio's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palisade Bio EBITDA Margin % Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 -4,912.40 0.00 0.00

Palisade Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PALI vs PBYI, NWBO, PROK: EBITDA Margin % Comparison

For the Biotechnology subindustry, Palisade Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Palisade Bio EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Palisade Bio's EBITDA Margin % falls into.


PALI
35GF Score
Palisade Bio Inc PALI
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palisade Bio EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Palisade Bio's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-16.768/0
= %

Palisade Bio's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-9.599/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Palisade Bio (PALI) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Palisade Bio and its competitors. According to the industry distribution chart, Palisade Bio ranks #999999 out of 944 companies in the Biotechnology industry.
Is Palisade Bio's EBITDA Margin % too high?
Palisade Bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, Palisade Bio ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Palisade Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Palisade Bio's EBITDA Margin % compare to PBYI and NWBO?
According to the Biotechnology industry distribution chart, Palisade Bio ranks #999999 out of 944 companies for EBITDA Margin %. This places Palisade Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Palisade Bio and its competitors. Palisade Bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palisade Bio stock overvalued right now?
Palisade Bio (PALI) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Palisade Bio's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Palisade Bio (PALI), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palisade Bio Business Description

Address 4600 South Syracuse Street, Suite 900, Denver, CO, USA, 80237
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
35GF Score

Get the complete analysis for PALI

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price